九强生物：公司目前着力推进欧美、东南亚等重点市场的产品注册和分销渠道建设工作

Group 1 - The company is focusing on advancing product registration and distribution channel development in key markets such as Europe, the United States, and Southeast Asia [1] - There is an increasing demand from overseas medical institutions for precise diagnostics and digital pathology, indicating a growing market opportunity [1] - The company has a solid foundation in software and hardware, positioning it well for international expansion in the field of pathology AI [1] Group 2 - The company emphasizes a clinical value-oriented approach and will continue to promote business collaborations with well-known leading companies [1] - Investors have inquired about the company's progress in expanding into overseas markets and the potential for AI pathology diagnostic technology to develop internationally [3] - Questions have been raised regarding the possibility of collaboration with major tech companies like Alibaba and Tencent [3]